Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Stanley T. Crooke sold 15,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $52.00, for a total value of $780,000.00. Following the transaction, the chief executive officer now directly owns 43,014 shares in the company, valued at approximately $2,236,728. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Ionis Pharmaceuticals, Inc. (IONS) traded up 3.46% during trading on Thursday, hitting $56.19. The company had a trading volume of 570,489 shares. The company has a market capitalization of $6.99 billion, a price-to-earnings ratio of 270.14 and a beta of 3.12. The stock has a 50-day moving average of $52.79 and a 200 day moving average of $48.81. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The firm had revenue of $104.15 million during the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.47) EPS. Equities analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/05/ionis-pharmaceuticals-inc-ions-ceo-stanley-t-crooke-sells-15000-shares-of-stock.html.

Several brokerages recently weighed in on IONS. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Monday, July 31st. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Laidlaw restated a “buy” rating and set a $65.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Finally, Barclays PLC began coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 target price for the company. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $49.11.

Hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC boosted its stake in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock valued at $109,000 after buying an additional 800 shares during the period. Hanseatic Management Services Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.2% in the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares during the period. WFG Advisors LP boosted its stake in shares of Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares during the period. Finally, Westpac Banking Corp bought a new stake in shares of Ionis Pharmaceuticals in the first quarter valued at approximately $171,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.